Search Result

Results for "

LPA receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Biochemical Assay Reagents (2) Calcium Channel (1) Caspase (1) Cyclophilin (1) Drug Isomer (1) Endogenous Metabolite (3) G Protein-coupled Receptor Kinase (GRK) (1) LPL Receptor (37) MDM-2/p53 (1) Mitosis (1) PPAR (1) Reactive Oxygen Species (ROS) (1) YAP (2)
By Research Areas:	Cancer (11) Cardiovascular Disease (5) Endocrinology (2) Infection (2) Inflammation/Immunology (13) Metabolic Disease (4) Neurological Disease (12)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, *LPA₃, and LPA₅, with IC₅₀*s of 94, 752, and 463 nM respectively .

HY-138453

ACT-1016-0707 LPA1 receptor antagonist 2	LPL Receptor	Inflammation/Immunology
ACT-1016-0707 (Compound 49) is an orally active and selective *LPA1* receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases .

HY-114379

AS2717638 2 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀ value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-16039

AM095 Maximum Cited Publications 13 Publications Verification	LPL Receptor	Inflammation/Immunology
AM095 is a selective *LPA₁* receptor antagonist. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-175084

1-Hexadecyl lysophosphatidic acid sodium 1-Hexadecyl LPA sodium; 1-Palmityl LPA sodium; LPA O-16:0 sodium	LPL Receptor	Metabolic Disease
1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium, an ether analog of lysophosphatidic acid (LPA), is a **LPA receptor** activator .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

HY-160823

2ccPA sodium 2ccPA18:1 sodium	LPL Receptor	Inflammation/Immunology Cancer
2ccPA sodium is a lysophosphatidic acid (LPA) receptor agonist. 2ccPA sodium modulates processes such as cell proliferation, migration, and apoptosis by activating LPA receptors and inhibiting autotaxin (ATX) enzyme activity. 2ccPA sodium is promising for research of cancers, inflammation, and fibrosis .

HY-N15794

AzoLPA ammonium	LPL Receptor	Neurological Disease
AzoLPA ammonium is a photoswitchable lipid that activates the Lysophosphatidic acid 1-5 (LPA1-5) receptors’ signaling .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-151392

LPA5 antagonist 2	LPL Receptor	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility *LPA5* (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

HY-16040

AM095 free acid Maximum Cited Publications 13 Publications Verification	LPL Receptor	Inflammation/Immunology
AM095 (free acid) is a potent *LPA1* receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-18641

Ki16198	LPL Receptor	Cancer
Ki16198 is a potent and orally active **LPA receptor** antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA₁ and LPA₃-induced inositol phosphate production with?K_i?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo .

HY-117959

TAK-615	LPL Receptor	Inflammation/Immunology
TAK-615 is a negative allosteric modulator (NAM) of the *LPA1* receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (K_d high affinity of 1.7 nM and K_d low affinity of 14.5 nM) .

HY-118539

NSC12404	LPL Receptor	Others
NSC12404 is a weak and specific **LPA₂ receptor** agonist .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective *lysophosphatidic acid receptor* 5** (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-167862A

UCM-05194 ammonium	LPL Receptor	Neurological Disease
UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC₅₀ = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice .

HY-167862

UCM-05194	Endogenous Metabolite	Neurological Disease
UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .

HY-137862

1-Oleoyl lysophosphatidic acid 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the **LPA receptors*. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA* receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-100676

GRI977143	LPL Receptor Caspase	Inflammation/Immunology Cancer
GRI977143 is a specific **LPA₂ receptor agonist, with an EC₅₀** of 3.3 μM .

HY-13285

Ki16425 5+ Cited Publications Debio 0719	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, *LPA1* and *LPA3* with K_is of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the *LPA*-induced activation of p42/p44 MAPK . Ki16425 can also inhibit *LPA*-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-139853

BMS-986278 1 Publications Verification AdmiLPArant	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic *LPA1* (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-13285R

Ki16425 (Standard)	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK . Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-150204

ONO-0740556	LPL Receptor	Others
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-119013

VPC32183	Endogenous Metabolite	Cardiovascular Disease
VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes .

HY-171906

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA 1-Arachidonoyl-sn-glycerol 3-phosphate; 1-Arachidonoyl LPA; LPA (20:4)	LPL Receptor	Inflammation/Immunology
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid containing arachidonic acid at the sn-1 position. It is a precursor to 1-arachidonoyl glycerol (1-Monoarachidin; HY-130567) . 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM . It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS . It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate .

HY-W783254

C18 LPA PA(18:0e/0:0)	G Protein-coupled Receptor Kinase (GRK) Calcium Channel	Cardiovascular Disease Cancer
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-107616

H2L5186303 2 Publications Verification	LPL Receptor Apoptosis	Inflammation/Immunology
H2L5186303 is a potent and selective *LPA₂* receptor antagonist with an IC₅₀ of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects .

HY-117779

DBIBB 2 Publications Verification	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent *LPA1* (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-107614

1-Oleoyl lysophosphatidic acid sodium 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor Mitosis	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a **LPA receptor** activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-100619A

BMS-986020 sodium 5+ Cited Publications AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619

BMS-986020 5+ Cited Publications AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-124072

HL001	Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species (ROS)	Cancer
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis .

HY-171906A

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium 1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium	LPL Receptor	Cancer
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the *LPA₂/EDG4* receptor (EC₅₀ of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present .

Cat. No.	Product Name	Type

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Cell Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83630

	EDG2 Antibody (YA3375) Lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, IP	Human
	EDG2 Antibody (YA3375) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EDG2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective *lysophosphatidic acid receptor* 5** (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high brain permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LPA receptor

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products